Soleus Capital Master Fund, L.P. 13D and 13G filings for NovoCure Limited:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-08 5:01 pm Purchase | 2026-03-31 | 13G | NOVOCURE LTD NVCR | Soleus Capital Master Fund, L.P. | 10,492,391 9.100% | 1,961,726 (+23.00%) | Filing |
| 2026-02-12 5:01 pm Sale | 2025-12-31 | 13G | NOVOCURE LTD NVCR | Soleus Capital Master Fund, L.P. | 8,530,665 7.600% | -1,114,207 (-11.55%) | Filing |
| 2025-11-07 4:00 pm Purchase | 2025-09-30 | 13G | NOVOCURE LTD NVCR | Soleus Capital Master Fund, L.P. | 9,644,872 8.600% | 2,740,570 (+39.69%) | Filing |
| 2025-08-05 5:00 pm Purchase | 2025-06-30 | 13G | NOVOCURE LTD NVCR | Soleus Capital Master Fund, L.P. | 6,904,302 6.200% | 1,382,888 (+25.05%) | Filing |
| 2025-04-01 5:00 pm Purchase | 2025-03-31 | 13G | NOVOCURE LTD NVCR | Soleus Capital Master Fund, L.P. | 5,521,414 5.000% | 5,521,414 (New Position) | Filing |